Vol.

No.

April 14, 2023Apr 14, 2023

DOWNLOAD THE PDF

Monica Bertagnolli’s Cancer Plan makes the most of her two roles: NCI director and leader of the National Cancer Program

Cover Story

Conversation with The Cancer Letter Free

Monica Bertagnolli’s Cancer Plan makes the most of her two roles: NCI director and leader of the National Cancer Program

By Paul Goldberg and Matthew Bin Han Ong

This point is easily overlooked: Monica Bertagnolli has two jobs, not one. She is the director of the National Cancer Institute and head of the National Cancer Program.

Clinical Trials & Tribulations

San Antonio Breast Cancer Symposium 2022 tackled big obstacles, recommended solutions for breast cancer progress

By Angela DeMichele, Rajarshi Sengupta and Carlos L. Arteaga

Guest Editorial

Mifepristone and the Administrative Procedure Act: Perspective of a former FDA commissioner and NCI director

By Norman E. "Ned" Sharpless

Conversation with The Cancer Letter Judiciary

Bipartisan Policy Center’s Anand Parekh: Rulings on USPSTF, mifepristone are ideological threats to evidence-based care

By Matthew Bin Han Ong

Clinical

Pragmatica-Lung, a landmark pragmatic trial with registrational intent, starts enrollment

By Jacquelyn Cobb

Free In the Archives

When cigarette filters were made of asbestos

In Brief

Georgetown’s Lombardi CCC to open Ralph Lauren Center for Cancer Prevention in Washington, DC

SWOG Cancer Research Network adds option for group co-chairs

UC Davis CCC receives first SPORE grant for immunotherapy in head and neck cancer

James P. Allison awarded Block Memorial Lectureship at The Ohio State

Francisco Sanchez-Vega awarded Health Equity Fellowship from Corning and MSKCC to explore disparities in cancer outcomes

Julia Agne, Arnab Basu, Kimberley Lee, Yuxuan Wang receive NCCN Young Investigator Award

Funding Opportunities

Harrington Discovery Institute opens call for 2024 Harrington Scholar-Innovator Award

Clinical Roundup

Keytruda + Cabometyx shows clinical benefit for head and neck squamous cell carcinoma in phase II trial

Medicaid “cliff” adds to racial and ethnic disparities in care for near-poor seniors

UCLA-led research shows that prior treatments influence immunotherapy response in advanced melanoma

New Century Health and Neighborhood Health Plan of Rhode Island study finds increased hypofractionation uptake

Drugs & Targets

mRNA cancer vaccine + Keytruda receives PRIME scheme designation from EMA for adjuvant treatment of high-risk stage 3/4 melanoma

ArteraAI and ACS form collaboration to use AI for designing personalized therapy

Adaptive Biotechnologies, Takeda form translational collaboration to measure minimal residual disease

Caris Life Sciences, Flare Therapeutics form precision oncology collaboration

University of Florida Health, Nuance Communications form collaboration focused on AI in radiology

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 35 - September 25, 2026